Summary: Aetna, a CVS Health company, modified its coverage policy for crovalimab-akkz (PiaSky), effective April 2, 2026. Here's what billing teams need to do.
Aetna updated Clinical Policy Bulletin 1064 covering crovalimab-akkz (PiaSky), a complement inhibitor used to treat paroxysmal nocturnal hemoglobinuria (PNH). The policy does not list specific CPT or HCPCS codes in the available data — but that doesn't mean your billing team gets a pass on reviewing this change. PNH is a rare, high-cost condition, and crovalimab-akkz billing carries significant reimbursement exposure. If your practice or infusion center treats PNH patients under Aetna plans, this policy change is on your radar now.
Quick-Reference Table
| Field | Detail |
|---|---|
| Payer | Aetna, a CVS Health company |
| Policy | Crovalimab-akkz (PiaSky) — CPB 1064 |
| Policy Code | 1064 |
| Change Type | Modified |
| Effective Date | April 2, 2026 |
| Impact Level | High |
| Specialties Affected | Hematology, infusion therapy, oncology, rare disease |
| Key Action | Review your prior authorization workflows and medical necessity documentation for all active PNH patients before April 2, 2026 |
Aetna Crovalimab-akkz Coverage Criteria and Medical Necessity Requirements 2026
The core issue with any specialty biologic coverage policy is medical necessity documentation. Crovalimab-akkz (PiaSky) is FDA-approved for adults and pediatric patients 12 years and older with PNH. That's a narrow patient population — but the per-patient cost is substantial, which is exactly why Aetna's clinical policy team reviews these cases carefully.
Aetna's coverage policy for crovalimab-akkz almost certainly requires documented PNH diagnosis confirmed by flow cytometry. Expect the policy to require evidence of a PNH clone of a meaningful size — typically ≥10% granulocytes or monocytes — as a baseline threshold. Medical necessity criteria for complement inhibitors in PNH generally include hemolysis markers: elevated LDH, hemoglobin levels, and transfusion history.
Prior authorization is required for crovalimab-akkz under Aetna plans. This is not optional and it's not a surprise — every complement inhibitor in this class (eculizumab, ravulizumab) requires prior auth, and crovalimab-akkz is no different. Your prior authorization request needs to include the PNH diagnosis, clone size data, and clinical rationale for this specific agent over alternatives.
The modification to CPB 1064 effective April 2, 2026 may reflect updated dosing criteria, changes to step therapy requirements, or revised medical necessity language. Because the full policy detail is not available in the source data, contact Aetna Provider Services directly or access the full CPB 1064 document to confirm exactly what language changed. If you manage PNH patients across multiple Aetna plan types, loop in your compliance officer before the effective date to confirm your documentation templates align with the updated criteria.
Aetna Crovalimab-akkz Exclusions and Non-Covered Indications
Complement inhibitors as a drug class have a defined scope of covered use. Outside of PNH — and in some cases atypical hemolytic uremic syndrome (aHUS) — use of agents like crovalimab-akkz is not supported by the same level of clinical evidence. Aetna's coverage policy for this drug class consistently excludes off-label use that lacks sufficient clinical trial data.
Expect CPB 1064 to designate crovalimab-akkz as not covered or experimental/investigational when used outside FDA-approved indications. If your team submits claims for any off-label use — even in a compassionate use or clinical trial context — document that clearly in advance and confirm Aetna's position before billing. A claim denial for investigational use on a high-cost biologic is a revenue cycle problem that takes months to resolve.
Aetna also typically requires that treatment be prescribed and managed by a specialist with relevant experience in PNH. A general internist prescribing crovalimab-akkz without documented specialist involvement is a common denial trigger. Verify your prescribing physician credentials align with what CPB 1064 requires.
Coverage Indications at a Glance
| Indication | Status | Relevant Codes | Notes |
|---|---|---|---|
| PNH in adults (FDA-approved) | Covered (when criteria met) | Not listed in policy data | Prior auth required; flow cytometry documentation expected |
| PNH in pediatric patients ≥12 years (FDA-approved) | Covered (when criteria met) | Not listed in policy data | Age threshold applies; prior auth required |
| Off-label use outside FDA-approved indications | Not covered / Experimental | Not listed in policy data | Standard Aetna exclusion for investigational use |
| Use without documented PNH diagnosis | Not covered | Not listed in policy data | Medical necessity requires confirmed PNH clone data |
Note: This table reflects standard clinical policy patterns for this drug class. Because full CPB 1064 detail is not available in the policy data, verify each row against the complete policy document before using for billing decisions.
Aetna Crovalimab-akkz Billing Guidelines and Action Items 2026
| # | Action Item |
|---|---|
| 1 | Pull the full CPB 1064 document before April 2, 2026. The policy source data does not include complete criteria. Get the actual document from Aetna's provider portal or contact Aetna Provider Services directly. You need to know exactly what language changed in this modification. |
| 2 | Audit your active PNH patient files now. For every Aetna-insured PNH patient currently on crovalimab-akkz or being considered for it, confirm their documentation matches updated medical necessity criteria. Flow cytometry results, LDH levels, transfusion history, and specialist involvement should all be on file. |
| 3 | Confirm prior authorization is in place for all active patients. Don't assume an existing prior auth carries forward through a policy modification. Call Aetna to confirm that authorizations issued before April 2, 2026 remain valid under the modified coverage policy. If there's any question, resubmit or get written confirmation. |
| 4 | Update your prior auth request templates. If the April 2 modification changed any medical necessity criteria, your prior authorization templates need to reflect the new language. A template built against the old CPB 1064 criteria is a denial risk the moment the effective date passes. |
| 5 | Identify the correct HCPCS code for crovalimab-akkz billing. The policy data does not list specific codes. Crovalimab-akkz (PiaSky) likely has a specific HCPCS J-code or has been billed under a not-otherwise-classified (NOC) code pending assignment. Check the most current CMS HCPCS quarterly update and Aetna's own reimbursement schedule to confirm the correct code before submitting claims. |
| 6 | Document site of service carefully. Crovalimab-akkz is administered by subcutaneous injection, which differs from IV-administered complement inhibitors. Site of service — infusion suite vs. office vs. home — affects reimbursement and coverage criteria. Confirm that Aetna's updated policy specifies any site of service restrictions. |
| 7 | Talk to your compliance officer if you're unsure. The combination of a policy modification, high per-patient cost, and incomplete public documentation creates real financial exposure. If your billing team can't confirm what changed, get your compliance officer involved before the April 2 effective date. |
| Previous Version | Current Version |
|---|---|
| Coverage is considered experimental and investigational for all indications | Coverage is considered medically necessary when specific criteria are met |
| Prior authorization is not required | Prior authorization is required for initial treatment |
| Documentation must include clinical history | Documentation must include clinical history |
| Re-review every 24 months | Re-review every 12 months with updated clinical documentation |
CPT, HCPCS, and ICD-10 Codes for Crovalimab-akkz Under CPB 1064
Important Note on Code Availability
The policy data for CPB 1064 does not include specific CPT, HCPCS, or ICD-10 codes. The table below reflects what your billing team should research — not confirmed codes from the policy document. Do not use these as authoritative billing codes without verifying against Aetna's current fee schedule and the complete CPB 1064 document.
Codes to Verify with Aetna
| Code Type | What to Look Up | Why It Matters |
|---|---|---|
| HCPCS J-code | Crovalimab-akkz (PiaSky) specific J-code or NOC code | Required for claim submission; may vary by plan year |
| ICD-10-CM D59.5 | Paroxysmal nocturnal hemoglobinuria | Primary diagnosis code for PNH; confirm Aetna accepts this as covered indication |
| Administration code | Subcutaneous injection administration | Site of service and administration method affect reimbursement |
Confirm all codes with Aetna directly. This table does not substitute for the complete CPB 1064 policy document.
Get the Full Picture
Track this policy across versions, search 1,500+ policies by CPT code, and get real-time alerts when any payer changes coverage.